Chris Gemmiti is the Business Development Lead at the Wyss Institute for Biologically Inspired Engineering at Harvard University. With a focus in tissue engineering and regenerative medicine, he guides translation strategy and technology development as well as strategic partnering and company formation. He is also the Founder and Managing Director of Ridgewood Consulting LLC, a strategic and technical consulting group focusing on biologic and device development in the tissue engineering / regenerative medicine field.
Previously, Chris was the Product Director for the Oral Regeneration business unit at Organogenesis Inc (Canton, MA) where he was responsible for the launch of a new living cellular sheet, GINTUIT™. GINTUIT™ marked the first-ever approval of a manufactured allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA. The GINTUIT™ Biologics License Application (BLA) was approved in March 2012 as a combination product (biologic-device). In similar cross-functional leadership roles at Organogenesis, he developed multiple collagen biomaterials for various indications, such as hernia and oral surgery.
He is the Chair of the Industry Council for the journal Tissue Engineering, heads the Commercialization and Regulation working group for the Tissue Engineering and Regenerative Medicine International Society (TERMIS), is a member of the Alliance for Regenerative Medicine (ARM) and sits on the Biomedical Engineering Advisory Board at both Georgia Tech and Duke University.
Chris holds a BS in Biomedical Engineering from The Johns Hopkins University and PhD in Biomedical Engineering jointly conferred by the Georgia Institute of Technology’s College of Engineering and Emory University’s School of Medicine. His thesis work centered on the development of tissue engineered articular cartilage using a novel bioreactor system, which was later patented. A minor in Management and Certificate of Engineering Entrepreneurship was also granted by Georgia Tech’s College of Management.
Awards, Honors and Press:
Bioreactor and methods for tissue growth and conditioning
Application number: 20050009179
Abstract: A bioreactor and methods of using same for making tissue constructs and for conditioning tissue-engineered constructs and harvested tissues such as cryopreserved tissues. The bioreactor allows for static and dynamic culture/ conditioning. The bioreactor is dual chambered (one chamber above and one below the cells or construct) to allow for application of biochemical and/or biomechanical stimuli to each side of the cells/construct.
Filed: February 26, 2004
Issued: January 13, 2005
Inventors: Christopher Gemmiti, Robert Guldberg
1: Gemmiti CV, Guldberg RE. Shear stress magnitude and duration modulates matrix
composition and tensile mechanical properties in engineered cartilaginous tissue.
Biotechnol Bioeng. 2009 Nov 1;104(4):809-20. doi: 10.1002/bit.22440. PubMed PMID:
19591192; PubMed Central PMCID: PMC2753758.
See full article below.
2: Pierre J, Gemmiti CV, Kolambkar YM, Oddou C, Guldberg RE. Theoretical analysis
of engineered cartilage oxygenation: influence of construct thickness and media
flow rate. Biomech Model Mechanobiol. 2008 Dec;7(6):497-510. Epub 2007 Nov 13.
PubMed PMID: 17999099.
3: Gemmiti CV, Guldberg RE. Fluid flow increases type II collagen deposition and
tensile mechanical properties in bioreactor-grown tissue-engineered cartilage.
Tissue Eng. 2006 Mar;12(3):469-79. PubMed PMID: 16579680.
Georgia Institute of Technology & Emory University, Atlanta, GA (2001-2006)
• Doctor of Philosophy in Biomedical Engineering (Orthopaedic Regenerative Medicine).
• Minor in Management, Graduate Certificate in Engineering Entrepreneurship.
• NSF Program Fellow - Technological Innovation: Generating Economic Results (TI:GER): Entrepreneurship program to commercialize thesis technology.
The Johns Hopkins University, Baltimore, MD (1993-1997)
• Bachelor of Science, Biomedical Engineering
• Bachelor of Science, Engineering Mechanics